SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conferen ...

Financial Performance - SI-BONE, Inc. announced preliminary unaudited revenue for Q4 2025 and the full year 2025, details to be provided in the attached press release[6] - The financial statements and exhibits related to the earnings report are included in the Form 8-K filing[8] Investor Relations - The company plans to meet with investors and analysts during the week of January 12, 2026, to discuss performance using presentation materials[7]

Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20%SANTA CLARA, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2025. Fourth Quarter 2025 Summary (any comparisons are to the prior year period) Worldwide revenue be ...

SI-BONE, Inc. (NASDAQ:SIBN) is one of the stocks Jim Cramer shared his takes on. A caller asked about the company during the episode’s lightning round, and Cramer replied: “Yeah, okay, so, you have to understand, this is a great, great speculation, I mean, terrific. And I’m glad you brought it to our viewers’ attention. I myself am going to huddle with research director Ben Stoto… and we are going to get to the bottom of this because I keep hearing this company’s name over and over and over again.” Pix ...

Core Insights - SI-Bone Inc. (NASDAQ:SIBN) shares experienced a 3.65% increase in after-hours trading, closing at $21.14, following a regular trading session close of $20.40, which was up 2.15% [1] Executive Share Sales - Three executives sold shares to cover tax obligations from restricted stock unit vesting, with Chief Financial Officer Anshul Maheshwari selling 5,229 shares for a total of $102,710.61 [2] - Senior Vice President and Chief Legal Officer Michael Pisetsky sold 3,460 shares totaling $67,896.05, while President of Commercial Operations Anthony Recupero sold 3,677 shares for $72,143.84 [3] Trading Metrics and Performance - SI-Bone has a Relative Strength Index (RSI) of 62.48 and a 12-month return of 44.48%, indicating strong performance and an upward trend [5] - The company's market capitalization is approximately $885.2 million, with shares trading between a 52-week high of $21.06 and a low of $12.50 [5] - Currently, SIBN is trading at 92.2% of its 52-week range, suggesting it is near its annual highs [6] Analyst Ratings - Analysts from Truist Securities, Canaccord Genuity, Needham & Company, and Morgan Stanley have maintained bullish ratings and raised price targets for SIBN [6] - Benzinga's Edge Stock Rankings indicate a positive price trend for SIBN across all time frames [7]

Core Viewpoint - Needham analyst David Saxon has raised the price target for SI-Bone (SIBN) to $27 from $24 while maintaining a Buy rating on the shares, indicating confidence in the company's growth potential [1] Group 1: Price Target and Ratings - The price target for SI-Bone has been increased to $27 from $24 [1] - SI-Bone has been added to Needham's 'Conviction List' and is named as the firm's '2026 Top Pick' [1] Group 2: Growth Potential - Needham believes SI-Bone can deliver potential upside to estimates in the near term, which is expected to enhance profitability [1] - Upcoming product launches are anticipated to drive active surgeon adoption across SI-Bone's portfolio, leading to higher utilization [1]

Core Viewpoint - SiBone (SIBN) is identified as a potential stock pick due to a recent "golden cross" event, indicating a bullish trend from a technical perspective [1]. Technical Analysis - A "golden cross" occurs when a short-term moving average (50-day) crosses above a long-term moving average (200-day), suggesting a potential bullish breakout [2]. - The formation of a golden cross involves three stages: a downtrend that bottoms out, the crossover of moving averages, and subsequent upward momentum [3]. - The golden cross is contrasted with a "death cross," which indicates potential bearish momentum [3]. Performance Metrics - SIBN has experienced a rally of 26.7% over the past four weeks, indicating strong upward momentum [4]. - Currently, SIBN holds a 3 (Hold) rating on the Zacks Rank, suggesting it may be poised for further breakout [4]. - Earnings expectations for SIBN have improved, with five upward revisions and no downward changes in the last 60 days, leading to an increase in the Zacks Consensus Estimate [4]. Investment Consideration - Given the significant technical indicators and positive earnings estimate movements, SIBN is recommended for inclusion on investors' watchlists [6].

Summary of SI-BONE FY Conference Call (December 02, 2025) Company Overview - **Company**: SI-BONE (NasdaqGM:SIBN) - **Industry**: Medical Technology, specifically focused on orthopedic devices and surgical solutions Key Points and Arguments Financial Performance - **Q3 Revenue Growth**: Achieved a total revenue growth of **21%** year-over-year, indicating strong business performance [12] - **Physician Engagement**: Notable **27%** increase in the number of physicians performing procedures, with **330 more surgeons** participating, totaling over **1,500 surgeons** in Q3 2025 [12] - **Profitability**: The company has reported four consecutive quarters of adjusted EBITDA profitability and has reached net cash break-even in recent quarters [12] Product and Market Strategy - **Innovative Products**: The company has established a reputation for innovation, with over **180 peer-reviewed publications** supporting the safety and efficacy of its products [14] - **Sales Strategy**: Utilizes a hybrid sales approach with **88 territory managers** and over **300 third-party agents** to expand market reach [13] - **Diversification**: The company has diversified its product offerings beyond SI Joint Fusion to include pelvic fixation and other breakthrough devices, mitigating risks associated with patent expirations [21][22] Patent and Competitive Landscape - **Patent Expiration Concerns**: Management expressed confidence regarding patent expirations, noting that the majority of sales come from products with patents extending through **2034-2035** [21] - **Competitive Positioning**: The company is focused on developing a robust pipeline of innovative products to maintain competitive advantages [22] Future Growth Opportunities - **Procedure Expansion**: Currently, **25%** of SI joint surgeons are performing multiple procedure types; there is potential to increase this to **50%** [30] - **New Product Launches**: A new product targeting a significant unmet clinical need in spine surgery is expected to launch in the second half of **2026**, which could further enhance growth [31] - **Market Penetration**: The company aims to increase its penetration in the SI Joint Fusion market from **10%** to potentially **15-20%** over time [60] Reimbursement and Regulatory Environment - **Reimbursement Increases**: Recent changes in reimbursement policies are expected to provide tailwinds, including a **30%** higher reimbursement for pelvic ring fracture cases and a **17%** increase for SI Joint Fusion procedures starting January 1, 2026 [52][53] - **Outpatient Opportunities**: The shift of many inpatient procedures to outpatient settings presents additional growth opportunities, particularly for the Granite product [54] Gross Margin and Operational Efficiency - **Gross Margin Performance**: The company reported gross margins exceeding **78%**, driven by better-than-expected average selling prices (ASP) and supply chain efficiencies [80] - **Future Margin Expectations**: Management anticipates maintaining gross margins around **78%** over the next few years, with potential for improvement as new products scale [81] Investment and R&D Focus - **Long-term Growth Strategy**: The company plans to continue investing in R&D to support its pipeline of new products, particularly in the area of compromised bone solutions [91] - **Operating Leverage**: Expected operating leverage of **1.5 times** revenue growth over operating expenses, indicating a focus on maintaining healthy adjusted EBITDA margins [90] Additional Important Insights - **Market Size**: The Granite product targets a **billion-dollar** market, with significant potential for growth as the company expands its offerings [37] - **Sales Force Integration**: New products are expected to be easily integrated into the existing sales force, potentially enhancing overall market attention and sales [47] This summary encapsulates the key insights from the SI-BONE FY Conference Call, highlighting the company's strong performance, innovative strategies, and future growth potential in the medical technology sector.

Core Insights - SI-BONE, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with a management-hosted fireside chat [1] - The company is a leader in developing technologies for surgical treatment of sacropelvic disorders, having supported over 4,900 physicians and performed over 135,000 procedures since 2009 [3] Company Overview - SI-BONE, Inc. specializes in minimally invasive SI joint surgery, having pioneered the iFuse Implant System [3] - The company has a strong clinical foundation with over 180 peer-reviewed publications, including four randomized controlled trials [3] - SI-BONE has expanded its offerings to adjacent markets, including adult deformity and pelvic trauma [3] Conference Participation - Investors can register to listen to the conference call and access a live audio webcast on the company's website [2] - The webcast will be archived for at least 90 days post-event [2]

Core Points - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories - **User Experience** - Enabling Javascript and cookies is crucial for a seamless browsing experience [1] - Ad-blockers can hinder access to certain content, suggesting a need for users to disable them [1]